Overview
High-performance neurostimulator
The lntellis™ with AdaptiveStim™ rechargeable neurostimulator is powered by proprietary Overdrive™ battery technology. It is designed to overcome limitations with other SCS systems and is optimized for the increased energy demands of High Dose (HD) therapy.
- Smallest fully implantable spinal cord neurostimulator
- <1 hour recharge — empty to full (approximate time)1
- Improved battery performance with minimal capacity fade (<5%)1
- Designed for patient comfort and more flexible placement during the implant
- AdaptiveStim™ technology automatically adjusts the therapy as your patient moves, delivering a personalized treatment based on seven unique body positions.
- Snapshot™ reporting, powered by AdaptiveStim™ technology, allows physicians to objectively monitor a patient's progress.
9-year Overdrive™ battery data1
Medtronic is the only SCS manufacturer to offer this proprietary, nontraditional lithium ion battery chemistry.
Overdrive™ Battery Technology
- Faster recharge*
- Minimal fade*
- Overdischarge protection
What could your patients do with more time?
~1 hour recharge
from empty to full
up to
3x faster
than traditional lithium ion batteries*
Patient can recharge
a completely discharged device
more than
95%1
battery capacity
at 9 years1, independent of therapy parameters or recharge preferences
Choose innovative battery technology
Improvements made to benefit your patients' needs and comfort
Implant depth
of up to
3 cm
provides versatility and patient comfort
Decreased
revisions
due to flipped batteries or over-discharged batteries
Meets the demands of current and future workflows
including optimization for increased energy demands of HD therapies
Unrivaled battery chemistry performance
Our Overdrive™ battery technology has a proprietary chemistry compared with SCS competitor batteries that are based on conventional Li ion chemistry. Our design allows for rapid recharge with minimal impact to the battery capacity at 9 years of use even with full discharge.
Under daily, empty-to-full charge and discharge testing:
- Medtronic’s Intellis™ Overdrive™ battery technology maintained 95% of the original capacity at 9 years and 3,200 cycles.1,2
- The tested Competitor X spinal cord stimulators lost 30% of the capacity after only 3 years and 1,000 cycles.1,2
- The Intellis™ devices can be recharged in ~1 hour from empty to full vs. up to 4 hours with the tested Competitor X devices.
Thus, patients will have a more consistent recharge interval and faster recharge experience, even under the most aggressive stimulation conditions.
Overdrive Intellis
Manufacturer X
Compatible products and features
Wireless External Neurostimulator
- Wireless, sterile single-use external neurostimulator simplifies testing during trial and implant
- Designed for patient comfort and convenience
| Model Number | 97725 |
|---|---|
| Weight | 71g (2.5oz) |
| Length | 79mm (3.1in) |
| Width | 74mm (2.9in) |
| Battery Type | Non-rechargeable |
| Thickness | 20mm (0.8in) |
Clinician Programmer
- Secure, wireless programming outside the sterile field
- Tailored programming workflows
- Electronic transfer of a variety of reports
- Bluetooth® communication§
- Requires the use of the Intellis™ clinician programmer app and communicator device
Combined Patient Programmer and Recharger
- Recharge from fully depleted battery
- Easy-to-adjust therapy
- Easy-to-read interface
- Large, pliable recharge antenna designed for patient comfort
Compatible
products
- 1x8 Vectris™ and Vectris™ SureScan™ MRI percutaneous leads and INJEX™ anchoring system models 97791 and 97792
- 16-electrode Specify™ SureScan™ MRI surgical leads
Intellis™ with
AdaptiveStim™ technology
| Model | 97715 |
|---|---|
| Channels | 2 |
| Volume | 13.9cc |
| Height | 57.1mm (2.2in) |
| Width | 47.2mm (1.9in) |
DTM™ SCS therapy
DTM™ SCS therapy is a proprietary therapy inspired by science and rooted in pre-clinical research, and adapted to provide superior clinical outcomes.
The DTM™ SCS 12-month RCT proved sustained superiority compared to conventional stimulation.3
- DTM™ SCS has an 84% back pain responder rate at 12-months.†
- DTM™ SCS has a 69% profound back pain response rate (≥80% pain relief) at 12 months.†
Unmatched full-body MRI access
- SureScan™ MRI technology allows MRI scans anywhere on the body enabling diagnostic care.‡
- Provide patients the same access as non-implanted patients‡ — now and in the future.
- Shielded leads and proprietary device safeguards help patients safely get an MRI.‡
- Access matters — 98% of patients are expected to need at least 1 MRI within 10 years of implant.4
Manuals and technical guides
Access prescriber, implant, MRI, and other manuals on the Medtronic Manual Library. Search by the product name (Intellis™) or model number (97715).
Read about DTM™ SCS
Click to learn more about DTM™ SCS, a proprietary waveform supported by pre-clinical research and clinical research delivering Superior Pain Relief. Proven.1
Learn more
Visit Medtronic Academy
and access detailed product information, including spec sheets, videos, and presentations.
Visit Medtronic Academy
*
Compared to traditional lithium ion batteries
†
Descriptive comparison, including studies with similar design (RCT; randomization >100 subjects; comparing 2 SCS therapies; with at least 12-months follow up) and patient populations (inclusion/exclusion criteria; baseline demographics) with back pain responder rates reported. This is not based on a statistical analysis of outcomes between studies.
‡
Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.
§
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.™
1
R131649 RS2 Lithium-Ion Overdrive™ Rechargeable Battery DVT Report
2
Chao Hu, et. al. Remaining useful life assessment of lithium-ion batteries in implantable medical devices. Journal of Power Sources. January 31, 2018, Volume 375, pgs118-130.
3
Fishman M, Cordner H, Justiz R, et al. 12-Month Results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1–12. doi: 10.1111/papr.13066.
4
Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537.